Gastrazole

• UNSPSC Description:

  Gastrazole (JB95008) is potent and selective CCK2/gastrin receptor antagonist. Gastrazole can decrease the level of gastric acid. Gastrazole inhibits the Gastrin-stimulated growth of pancreatic cancer[1][2].

• Target Antigen:

  Cholecystokinin Receptor

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein;Neuronal Signaling

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/gastrazole.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(C(C=C(NC=N1)C1=C2)=C2C(NCC3CCCCCC3)=O)N[C@H](C(NC4=CC(C(O[Na])=O)=CC(C(O[Na])=O)=C4)=O)CC(C=CC=C5)=C5F

• Molecular Weight:

  687.63

• References & Citations:

  [1]Chau I, et, al. Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials. Br J Cancer. 2006 Apr 24;94(8):1107-15.|[2]Rudholm T, et, al. Release of regulatory gut peptides somatostatin, neurotensin and vasoactive intestinal peptide by acid and hyperosmolal solutions in the intestine in conscious rats. Regul Pept. 2009 Jan 8;152(1-3):8-12.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  Phase 3

• CAS Number:

  862583-15-1